SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that …
Author: Business Wire
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
Ocular Therapeutix™ To Report Fourth Quarter and Year End 2020 Financial Results
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today…
Iveric Bio to Present at the Cowen 41st Annual Health Care Conference
NEW YORK–(BUSINESS WIRE)–Iveric Bio announced that Glenn Sblendorio, CEO, and Pravin Dugel, CSO, CBO, will participate in a fireside chat at the Cowen Conference on March 4.
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for t…
EyeSouth Partners Expands Presence in North Georgia With North Georgia Eye Clinic Affiliation
ATLANTA–(BUSINESS WIRE)–EyeSouth Partners (“EyeSouth” or the “Company”) is pleased to announce that it has completed an affiliation with North Georgia Eye Clinic (“NGEC”). The affiliation represents EyeSouth’s ninth in the state of Georgia and twenty…
Takeda Fornece Atualizações sobre Testes Clínicos da Fase 1/2 de Candidatos à Vacina para COVID-19 da Novavax e Moderna no Japão
OSAKA, Japão–(BUSINESS WIRE)–A Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) anunciou hoje que o primeiro indivíduo foi dosado na fase 1/2 do estudo de imunogenicidade e segurança da vacina candidata para COVID-19 da Novavax (TAK-019) no …
Takeda proporciona información actualizada sobre los ensayos clínicos de fase 1/2 de las candidatas a vacunas contra la COVID-19 de Novavax y Moderna en Japón
OSAKA, Japón–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ha anunciado hoy la administración de la primera dosis en su estudio de inmunogenicidad y seguridad de fase 1/2 de la vacuna candidata contra la COVID-19 de Novava…
Takeda présente des mises à jour sur les essais cliniques de Phase 1/2 portant sur les candidats vaccins contre la COVID-19 de Novavax et Moderna au Japon
OSAKA, Japon–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) annonce aujourd’hui le dosage du premier patient dans son étude de Phase 1/2 portant sur l’immunogénicité et l’innocuité du vaccin candidat contre la COVID-19 de N…
Takeda informiert über den aktuellen Stand der klinischen Phase 1/2-Studien mit den COVID-19-Impfstoffkandidaten von Novavax und Moderna in Japan
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) gab heute bekannt, dass der erste Proband im Rahmen der Phase-1/2-Studie zu Sicherheit und Immunogenität des COVID-19-Impfstoffkandidaten (TAK-019) von Novavax in …
Riassunto: Takeda fornisce aggiornamenti sugli studi clinici di fase 1/2 dei candidati vaccini anti COVID-19 di Novavax e Moderna in Giappone
OSAKA, Giappone–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) oggi ha annunciato l’inoculazione del primo soggetto dello studio di fase 1/2 su immunogenicità e sicurezza del candidato vaccino anti COVID-19 di Novavax (TAK-…
STAAR Surgical Reports Fourth Quarter and Full Year 2020 Results
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the fourth quarter and fi…
Samenvatting: Takeda geeft updates over fase 1/2 klinische onderzoeken van Novavax ’en Moderna’s COVID-19-vaccinkandidaten in Japan
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) heeft vandaag aangekondigd dat de eerste proefpersoon werd gedoseerd in zijn fase 1/2 immunogeniteits- en veiligheidsonderzoek van Novavax ‘COVID-19-vaccin kandid…
Global Artificial Cornea and Corneal Implant Market (2021 to 2026) – Shortage of Corneal Donors Presents Opportunities – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Artificial Cornea and Corneal Implant Market by Type (Human Cornea, Artificial Cornea), Transplant Type (Penetrating Keratoplasty, Endothelial Keratoplasty), Disease Indication, End Users (Hospitals, Specialty Clinics &…
Iveric Bio to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Wednesday, March 3, 2021
NEW YORK–(BUSINESS WIRE)–Iveric Bio announced that it will report its fourth quarter and full year 2020 financial and operating results on Wednesday, March 3, 2021.
Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today a…
Sunvera Group Announces New Partnership with Kellis Eye & Laser Center
BINGHAM FARMS, Mich.–(BUSINESS WIRE)–Sunvera Group expands platform into Ohio
Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates in Japan
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced today that the first subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax’ COVID-19 vaccine candidate (TAK-019) in Japan. Earlie…
Alcon Reports Fourth Quarter and Full Year 2020 Results
GENEVA–(BUSINESS WIRE)–Alcon Reports Fourth Quarter and Full Year 2020 Results
NeurOptics Launches Virtual Pupillometry Education Platform
IRVINE, Calif.–(BUSINESS WIRE)–NeurOptics launches virtual education symposium to share role pupillometry and NPi play in the screening of patients at risk of neurological injury.